Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

DNA alteration-based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in high-risk group.

Narasimhaiah D, Legrand C, Damotte D, Remark R, Munda M, De Potter P, Coulie PG, Vikkula M, Godfraind C.

Cancer Med. 2019 Jun;8(6):3036-3046. doi: 10.1002/cam4.2122. Epub 2019 Apr 25.

2.

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Liénart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stockis J, van der Woning B, De Haard H, Saunders M, Coulie PG, Savvides SN, Lucas S.

Science. 2018 Nov 23;362(6417):952-956. doi: 10.1126/science.aau2909. Epub 2018 Oct 25.

PMID:
30361387
3.

Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.

Dheur MS, Poirel HA, Ameye G, Tilman G, Saussoy P, Defour JP, Camboni A, Van Den Neste E, Coulie PG, van Baren N.

Leuk Lymphoma. 2019 Apr;60(4):1043-1052. doi: 10.1080/10428194.2018.1508663. Epub 2018 Oct 2.

PMID:
30277098
4.

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.

Stockis J, Liénart S, Colau D, Collignon A, Nishimura SL, Sheppard D, Coulie PG, Lucas S.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10161-E10168. doi: 10.1073/pnas.1710680114. Epub 2017 Nov 6.

5.

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P.

Trends Immunol. 2017 Aug;38(8):577-593. doi: 10.1016/j.it.2017.05.006. Epub 2017 Jun 10. Review.

PMID:
28610825
6.

Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA.

Dedobbeleer O, Stockis J, van der Woning B, Coulie PG, Lucas S.

J Immunol. 2017 Jul 15;199(2):391-396. doi: 10.4049/jimmunol.1601882. Epub 2017 Jun 12.

7.

A new transcript in the TCRB locus unveils the human ortholog of the mouse pre-Dß1 promoter.

Lethé B, Snauwaert S, Bricard O, Schröder D, Gomard T, Hames G, Muller C, Lurquin C, Gauthy E, Essaghir A, Vandekerckhove B, Coulie PG.

Immun Inflamm Dis. 2017 Sep;5(3):346-354. doi: 10.1002/iid3.172. Epub 2017 May 15.

8.

Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, Heinzerling L, Sotlar K, Coulie P, Schuler G, Schuler-Thurner B.

JCI Insight. 2017 Apr 20;2(8). pii: 91438. doi: 10.1172/jci.insight.91438. eCollection 2017 Apr 20.

9.

Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes.

Houddane A, Bultot L, Novellasdemunt L, Johanns M, Gueuning MA, Vertommen D, Coulie PG, Bartrons R, Hue L, Rider MH.

Cell Signal. 2017 Jun;34:23-37. doi: 10.1016/j.cellsig.2017.02.019. Epub 2017 Feb 22.

PMID:
28235572
10.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

11.

Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.

Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D.

Cancer Immunol Immunother. 2016 Oct;65(10):1177-88. doi: 10.1007/s00262-016-1877-7. Epub 2016 Aug 11.

PMID:
27514672
12.

MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.

Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, Sleijfer S, Debets R.

J Immunol. 2016 Sep 15;197(6):2541-52. doi: 10.4049/jimmunol.1502024. Epub 2016 Aug 3.

13.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B.

J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x.

14.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

15.

The promise of immunostimulatory antibodies in head and neck cancer.

Machiels JH, Coulie PG.

Lancet Oncol. 2016 Jul;17(7):856-857. doi: 10.1016/S1470-2045(16)30106-1. Epub 2016 May 27. No abstract available.

PMID:
27247227
16.

AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model.

Cochez PM, Michiels C, Hendrickx E, Van Belle AB, Lemaire MM, Dauguet N, Warnier G, de Heusch M, Togbe D, Ryffel B, Coulie PG, Renauld JC, Dumoutier L.

Eur J Immunol. 2016 Jun;46(6):1449-59. doi: 10.1002/eji.201546070.

17.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

18.

Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells.

Huygens C, Liénart S, Dedobbeleer O, Stockis J, Gauthy E, Coulie PG, Lucas S.

J Biol Chem. 2015 Aug 14;290(33):20105-16. doi: 10.1074/jbc.M115.655340. Epub 2015 Jun 30.

19.

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, Coulie PG, Lucas S.

Sci Transl Med. 2015 Apr 22;7(284):284ra56. doi: 10.1126/scitranslmed.aaa1983.

20.

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.

Bol KF, Mensink HW, Aarntzen EH, Schreibelt G, Keunen JE, Coulie PG, de Klein A, Punt CJ, Paridaens D, Figdor CG, de Vries IJ.

Am J Ophthalmol. 2014 Nov;158(5):939-47. doi: 10.1016/j.ajo.2014.07.014. Epub 2014 Jul 17.

21.

Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.

Abad S, Wieërs G, Colau D, Wildmann C, Delair E, Dhote R, Brézin AP, Kawakami Y, Coulie PG, van der Bruggen P.

Mol Vis. 2014 Jul 2;20:956-69. eCollection 2014.

22.

Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.

Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M.

Br J Anaesth. 2014 Jul;113 Suppl 1:i82-7. doi: 10.1093/bja/aet464. Epub 2014 Jan 23.

23.

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T.

Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review.

PMID:
24457417
24.

GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells.

Gauthy E, Cuende J, Stockis J, Huygens C, Lethé B, Collet JF, Bommer G, Coulie PG, Lucas S.

PLoS One. 2013 Sep 30;8(9):e76186. doi: 10.1371/journal.pone.0076186. eCollection 2013.

25.

Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial.

Forget P, Berlière M, van Maanen A, Duhoux FP, Machiels JP, Coulie PG, Bouche G, De Kock M; Ketorolac in Breast Cancer trial (KBCtrial) group.

Med Hypotheses. 2013 Oct;81(4):707-12. doi: 10.1016/j.mehy.2013.07.033. Epub 2013 Aug 9.

PMID:
23937996
26.

Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.

Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, Stainier A, Legrand C, Canon JL, Kremer Y, De Kock M.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S650-60. doi: 10.1245/s10434-013-3136-x. Epub 2013 Jul 25.

PMID:
23884751
27.

Is there a rationale for an anesthesiologist's role against cancer recurrence?

Forget P, Coulie PG, Retsky M, Demicheli R, Machiels JP, De Kock M.

Acta Anaesthesiol Belg. 2013;64(1):15-24. Review.

PMID:
23767173
28.

Ongoing adaptive immune responses in the microenvironment of melanoma metastases.

van Baren N, Coulie PG.

Ann N Y Acad Sci. 2013 May;1284:62-5. doi: 10.1111/nyas.12093.

PMID:
23651195
29.

An essential role for γ-herpesvirus latency-associated nuclear antigen homolog in an acute lymphoproliferative disease of cattle.

Palmeira L, Sorel O, Van Campe W, Boudry C, Roels S, Myster F, Reschner A, Coulie PG, Kerkhofs P, Vanderplasschen A, Dewals BG.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):E1933-42. doi: 10.1073/pnas.1216531110. Epub 2013 Apr 29.

30.

Lymphoid neogenesis in melanoma: What does it tell us?

van Baren N, Baurain JF, Coulie PG.

Oncoimmunology. 2013 Jan 1;2(1):e22505.

31.

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, Winkels G, Coulie PG, Punt CJ, Figdor CG, de Vries IJ.

Cancer Res. 2013 Feb 1;73(3):1063-75. doi: 10.1158/0008-5472.CAN-12-2583. Epub 2013 Jan 23.

32.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M.

Int J Cancer. 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13.

33.

Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2012 Nov-Dec;35(9):680-8. doi: 10.1097/CJI.0b013e31827338ea.

34.

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N.

Cancer Res. 2012 Aug 15;72(16):3997-4007. Epub 2012 Jul 31.

35.

Management of inflammatory bowel disease in pregnancy.

Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E.

J Crohns Colitis. 2012 Sep;6(8):811-23. doi: 10.1016/j.crohns.2012.04.009. Epub 2012 May 16. Review.

36.

TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.

Straetemans T, van Brakel M, van Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN, Lamers C, van Der Bruggen P, Coulie PG, Debets R.

Clin Dev Immunol. 2012;2012:586314. doi: 10.1155/2012/586314. Epub 2012 Feb 12.

37.

The determinants of tumour immunogenicity.

Blankenstein T, Coulie PG, Gilboa E, Jaffee EM.

Nat Rev Cancer. 2012 Mar 1;12(4):307-13. doi: 10.1038/nrc3246. Review.

38.

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A.

Mol Ther. 2012 May;20(5):1063-74. doi: 10.1038/mt.2012.11. Epub 2012 Feb 28.

39.

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Seremet T, Brasseur F, Coulie PG.

Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004. Review.

PMID:
21952282
40.

DNA methylation profiling reveals a predominant immune component in breast cancers.

Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart M, Sotiriou C, Fuks F.

EMBO Mol Med. 2011 Dec;3(12):726-41. doi: 10.1002/emmm.201100801. Epub 2011 Nov 16.

41.

Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use.

Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F.

Rheumatology (Oxford). 2011 Nov;50(11):1955-68. doi: 10.1093/rheumatology/ker302. Epub 2011 Sep 2. Review.

42.

Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples.

Lucas S, van Baren N, de Smet C, Coulie PG.

Int J Cancer. 2012 Apr 15;130(8):1960-6. doi: 10.1002/ijc.26198. Epub 2011 Aug 2.

43.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.

Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM.

J Transl Med. 2011 May 12;9:60. doi: 10.1186/1479-5876-9-60.

44.

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

Cipponi A, Wieers G, van Baren N, Coulie PG.

Cancer Immunol Immunother. 2011 Aug;60(8):1153-60. doi: 10.1007/s00262-011-1026-2. Epub 2011 May 7. Review.

PMID:
21553145
45.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

46.

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.

Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ.

Int J Cancer. 2011 Nov 15;129(10):2427-34. doi: 10.1002/ijc.25911. Epub 2011 Apr 20.

47.

Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.

de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G, Coulie PG, Lucas S.

Clin Cancer Res. 2011 Feb 15;17(4):841-8. doi: 10.1158/1078-0432.CCR-10-2227. Epub 2010 Dec 21.

48.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
49.

Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens.

Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der Bruggen P, Coulie P, De Plaen E.

Int J Cancer. 2010 Oct 1;127(7):1625-36. doi: 10.1002/ijc.25182.

50.

Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg.

Stockis J, Colau D, Coulie PG, Lucas S.

Eur J Immunol. 2009 Dec;39(12):3315-22. doi: 10.1002/eji.200939684.

Supplemental Content

Loading ...
Support Center